I agree withe Crusader. $0.10 to maybe $0.12. Not enough to recoup most of us. At least two doublings away from break even for the majority who bought in at $0.30. Very, very short of what it would take to hit the IPO's $1.20.
Consider the big picture. There Is No Market for this product. Worse, there will be no margin on it. EUA does not grant reimbursement. Don't get me wrong, I would really like to reduce the amount I've lost on Lumos. The bad decisions and waste of resources shown by this leadership is staggering.
Yay! They were approved for FebriDx. Too bad they missed the opportunity to be first to market. Now there are better, faster, platforms already locked into that space.
Yay! They have EUA on a covid/flu test. As the press release points out, a dozen other companies with proven manufacturing capabilities have the same test on the market. What the press release neglects to mention, these companies are scaling back on production.
That the company spent so much time, effort, and our investment cash getting approval on yet another covid/flu test it a kick in the shorts.
Add to My Watchlist
What is My Watchlist?
